Guided Therapeutics (GTHP) Liabilities and Shareholders Equity (2010 - 2026)

Guided Therapeutics has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $1.3 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 3.92% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (down 23.05% YoY) and the FY2025 annual result came in at $1.3 million, down 3.92% from the prior year.
• Liabilities and Shareholders Equity climbed to $1.3 million in Q4 2025 per GTHP's latest filing, from $903000.0 in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $3.9 million in Q3 2022 and troughed at $903000.0 in Q3 2025.
• A 5-year average of $1.9 million and a median of $1.7 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2021 and 2023: Liabilities and Shareholders Equity surged 548.9% in 2021, then sank 51.51% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $2.0 million in 2021, then soared by 65.0% to $3.4 million in 2022, then sank by 50.42% to $1.7 million in 2023, then decreased by 17.44% to $1.4 million in 2024, then retreated by 3.92% to $1.3 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.3 million, $903000.0, and $940000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.